UCB SA (OTCMKTS:UCBJY – Get Free Report) saw a large decline in short interest in the month of October. As of October 30th, there was short interest totaling 7,614 shares, a decline of 63.8% from the October 15th total of 21,017 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily trading volume, of 76,592 shares, the days-to-cover ratio is presently 0.1 days.
UCB Price Performance
OTCMKTS UCBJY opened at $163.75 on Monday. The business has a 50 day simple moving average of $131.08 and a 200 day simple moving average of $140.66. UCB has a 52-week low of $110.55 and a 52-week high of $168.76.
Analysts Set New Price Targets
A number of analysts recently weighed in on the stock. Zacks Research upgraded shares of UCB from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 27th. Jefferies Financial Group raised shares of UCB from a “moderate sell” rating to a “hold” rating in a research note on Monday, August 3rd. Two investment analysts have rated the stock with a Strong Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Buy”.
About UCB
UCB is a Belgian biopharmaceutical company headquartered in Brussels. Founded in 1928, it develops medicines for people with serious neurological and immune-mediated diseases, with research focused on areas such as epilepsy and inflammatory conditions. Its products include epilepsy treatments such as Briviact and Vimpat, as well as medicines for immune-mediated diseases, including Bimzelx and Cimzia. Product availability and approved uses vary by country. UCB serves patients and healthcare providers across international markets through its global operations.
See Also
- Five stocks we like better than UCB
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
